Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for X4 Pharmaceuticals (XFOR) over the last 3 years, with Q3 2025 value amounting to $15.9 million.

  • X4 Pharmaceuticals' Change in Acquisitions & Divestments rose 20219.05% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 42824.15%. This contributed to the annual value of $26.4 million for FY2024, which is 122250.0% up from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Change in Acquisitions & Divestments is $15.9 million, which was up 20219.05% from $28.2 million recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $28.2 million for Q2 2025, and its period low was $1.0 million during Q3 2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $9.4 million, with a median of $5.2 million in 2024.
  • As far as peak fluctuations go, X4 Pharmaceuticals' Change in Acquisitions & Divestments surged by 132000.0% in 2024, and later soared by 13500.0% in 2025.
  • Over the past 3 years, X4 Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $1.0 million in 2023, then skyrocketed by 1320.0% to $14.2 million in 2024, then grew by 11.73% to $15.9 million in 2025.
  • Its Change in Acquisitions & Divestments was $15.9 million in Q3 2025, compared to $28.2 million in Q2 2025 and $11.8 million in Q1 2025.